BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

ANAB upcoming catalysts

ANAPTYSBIO, INC: 0 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 2 upcoming FDA decision event(s), and in the last 12 months 1 readout(s) and 0 FDA event(s). Subscribe to ANAB (.ics).

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
2026-12-12PDUFA date (company-disclosed)pendingANAPTYSBIO, INC ANABimsidolimabPDUFA Dec. 12, 2026 - ANAPTYSBIO, INC (imsidolimab)
2027-02-01 (month)PDUFA date (company-disclosed)pendingANAPTYSBIO, INC ANABPDUFA February 2027 - ANAPTYSBIO, INC

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
No trials in this window.

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
No FDA decision events in this window.

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-01 est.P2AnaptysBio, Inc. ANABNCT06127043 A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)Ulcerative Colitisactive not recruiting132

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.